# Rakovina Therapeutics Adds AI Drug Discovery Advisor Role for Dr. Artem Cherkasov > Rakovina Therapeutics expanded Dr. Artem Cherkasov's advisory role with $160,000 a year, $60,000 in shares, and a joint Artemis webinar on November 18. - Published: 2026-11-12T11:00:49+00:00 - Section: Leadership - Author: News Desk - URL: https://newsforagent.com/news/2026-11-12/rakovina-cherkasov-ai-advisor-role - Source: [GlobeNewswire](https://www.globenewswire.com/news-release/2026/11/12/3401316/0/en/rakovina-therapeutics-expands-strategic-engagement-with-renowned-ai-drug-discovery-pioneer-dr-artem-cherkasov.html) ## Key takeaways - Dr. Artem Cherkasov will serve as Advisor AI Drug Discovery while remaining on Rakovina Therapeutics' Scientific Advisory Board. - Cherkasov will receive $160,000 per year, with $100,000 in cash and $60,000 in common shares under a consulting agreement effective November 15, 2026. - Rakovina Therapeutics and Artemis Therapeutics will host a joint webinar on November 18 featuring Kim Oishi, Frank Holler and Cherkasov. Rakovina Therapeutics expanded Dr. Artem Cherkasov's advisory engagement on November 12, 2026, adding the title Advisor AI Drug Discovery while he remains on its Scientific Advisory Board. The company said he will receive $160,000 per year, of which $60,000 is payable in common shares. [GlobeNewswire](https://www.globenewswire.com/news-release/2026/11/12/3401316/0/en/rakovina-therapeutics-expands-strategic-engagement-with-renowned-ai-drug-discovery-pioneer-dr-artem-cherkasov.html) published the announcement. ## Cherkasov's Expanded Role and Pay Terms Cherkasov will advise on AI-enabled drug discovery and development and conduct scientific and technical due diligence on new AI platforms, according to the announcement. The consulting agreement is effective November 15, 2026, for a term of up to 24 months. The services do not include investor relations, promotional or market-making activities. Under the arrangement, $100,000 is payable in cash in equal monthly instalments and $60,000, or $15,000 per quarter, is payable in common shares. Shares will be issued quarterly in arrears after the services for the quarter have been provided, with the number determined by dividing $20,000 by a deemed price per share that will not be less than the Discounted Market Price on the date of determination. No warrants will be issued. Cherkasov is a Non-Arm's Length Party of the company and is co-founder, director and Chief Technology Officer of Artemis Therapeutics Inc., which is expected to receive shares as consideration for the Artemis.AI licence announced on November 10, 2026. The issuance of shares is subject to TSX Venture Exchange acceptance, and the shares will be subject to a hold period of four months and one day from the date of issuance. "Art has been using AI to accelerate drug discovery for more than 20 years and has an internationally recognized track record, and few people are better placed to judge which AI technologies will deliver results in the lab," said Kim Oishi, Chief Executive Officer of Rakovina Therapeutics. ## Rakovina's AI Deals Before the Advisory Change Rakovina Therapeutics entered an exclusive worldwide licence agreement with Artemis Therapeutics to use its Artemis.AI platform for DNA-damage response oncology drug discovery, The future of trading reported on November 10, 2026. On October 28, 2026, Rakovina Therapeutics and Celvion Therapeutics completed an AI analysis using Celvion's EMphora platform to evaluate treatment strategies for Rakovina's ATR inhibitor program, TradingView reported. Rakovina Therapeutics appointed Dr. Ranjit Bindra to its Scientific Advisory Board, Financial Post reported on September 17, 2026. ## AI Drug Discovery Leadership Appointments Elsewhere DaltonTx appointed Melissa Landon as Chief Commercial Officer to lead commercial strategy, [GlobeNewswire](https://www.globenewswire.com/news-release/2026/11/12/3401272/0/en/daltontx-appoints-melissa-landon-as-chief-commercial-officer-to-drive-commercial-growth-and-strategic-partnerships.html) reported on November 12, 2026. Colait appointed Susan McNair as Senior Vice President, [EIN Presswire](https://www.einnews.com/pr_news/954796446/colait-appoints-susan-mcnair-as-senior-vice-president-strengthening-global-life-sciences-leadership) reported on November 5, 2026. BranchLab appointed Edgar Simard to its Scientific Advisory Board, [citybiz](https://www.citybiz.co/article/932258/branchlab-appoints-edgar-simard-to-scientific-advisory-board/) reported on November 10, 2026. ## Joint Webinar Set for November 18 Rakovina Therapeutics will host a joint webinar with Artemis Therapeutics on November 18 at 11:30AM PCT (Vancouver time) to discuss the recently announced collaboration between the two companies. The webinar will feature Kim Oishi, Frank Holler, CEO of Artemis, and Cherkasov. ## Companies in this story - Rakovina Therapeutics · website: https://www.rakovinatherapeutics.com --- News for Agent · https://newsforagent.com/llms.txt